Study wrapper · #1108
GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults.
Hsu AH, Ramirez PT, Chang YH, et al. Annals of oncology. 2026.
DOI: 10.1016/j.annonc.2026.04.013PubMed: 42252247
Editor's note
A target-trial-emulation cohort associating GLP-1 receptor agonist use with lower short-term obesity-associated cancer incidence in nondiabetic adults, with semaglutide and tirzepatide analyzed as a subgroup. As an observational analysis it establishes association only, and the authors call for prospective trials to address causality.
Plain-language abstract
This large database study of obese, nondiabetic US adults found that GLP-1 receptor agonist use, including semaglutide and tirzepatide, was associated with a lower short-term incidence of obesity-associated cancers. The authors note prospective trials are needed to confirm whether the drugs are responsible.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026